NEONasdaqServices-Testing LaboratoriesFiscal year ends December 31

NEOGENOMICS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026

$16.42−0.23 (-1.38%)

Close on Oct 19, 2026

Market cap: $2.15B
P/E (TTM): –
Dividend yield: –

NEOGENOMICS INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31
Revenue	727	661	592	510	484	444	409	277	240	232	100	87	66	60	43	34
Cost of Revenue	413	370	347	322	297	259	212	149	138	134	56	46	35	33	24	19
Gross Profit	314	290	245	188	187	186	197	127	102	98	44	41	32	27	19	16
Research & Development	37	31	27	30	22	8.23	8.49	3.00	3.64	4.65	4.20	2.69	2.44	2.28	0.54	–
Selling, General & Admin	365	344	314	311	284	192	175	114	94	88	45	36	26	23	19	19
Selling & Marketing	92	85	71	67	63	48	47	29	24	24	12	12	8.73	7.50	6.96	7.48
General & Administrative	273	260	243	243	221	144	128	85	70	64	34	24	17	16	12	11
Operating Expenses	430	382	352	346	306	200	184	117	99	96	49	38	29	26	20	19
Operating Income	-116	-92	-108	-158	-119	-14	13	10	2.90	2.16	-5.64	2.22	3.17	1.21	-0.41	-2.96
Interest Expense	3.75	6.62	6.91	7.58	8.22	7.02	3.71	6.23	5.54	–	0.85	0.99	0.99	1.15	0.77	0.71
Interest & Investment Income	9.07	18	17	6.08	–	–	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	0.30	-0.38	0.64	-0.21	-0.50	7.91	-4.63	0.01	-0.01	0	2.00	0.06	-0.99	-1.15	-0.77	-0.34
Merger & Restructuring Charges	0	6.66	11	4.52	0	0	–	–	–	–	–	–	–	–	–	–
Asset Impairment Charges	3.50	0	0	0	0	0	0	0	0	3.50	0	0	0	0	–	–
Gain (Loss) on Sale of Assets	-0.03	0.05	-0.29	-2.86	-0.61	-0.45	0	0	-1.06	0	–	–	–	–	–	–
Pretax Income	-110	-81	-97	-159	-15	-14	3.65	3.82	-2.65	-7.84	-4.49	1.29	2.19	0.07	-1.18	–
Income Tax Expense	-2.24	-1.95	-9.13	-15	-6.73	-18	-4.36	1.18	-2.25	-1.70	-1.95	0.16	0.15	0	0	–
Net Income	-108	-79	-88	-144	-8.35	4.17	8.01	2.64	-0.40	-6.14	-2.54	1.13	2.03	0.07	-1.18	-3.30
Net Income to Common	–	-79	-88	-144	-8.35	4.17	8.01	6.09	-11	-31	-2.66	1.13	2.03	–	–	–
EPS (Basic)(per share)	–	–	–	–	–	–	–	–	–	–	-0.04	0.02	0.04	0.00	-0.03	-0.09
EPS (Diluted)(per share)	–	–	–	–	–	–	–	–	–	–	-0.04	0.02	0.04	0.00	-0.03	-0.09
Shares Outstanding (Basic, Weighted)(shares)	128	127	126	124	120	109	100	86	79	78	61	53	48	45	43	–
Shares Outstanding (Diluted, Weighted)(shares)	128	127	126	124	120	112	104	92	79	78	61	56	53	49	43	–
EBITDA	–	–	–	–	–	12	33	26	18	18	1.10	7.56	7.36	4.85	–	–
Net Interest Income	–	–	–	–	–	–	–	–	5.54	10.00	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 43.9%
Operating margin: -8.9%
Net margin: -6.8%
Return on equity, FY2025: -12.4%

Financial strength

Current ratio: 3.60
Debt to equity: 0.48
Debt to assets: 27.7%
Cash to current liabilities: 137.5%

Valuation

P/E ratio: –
Price to sales: 2.80
Price to book: 2.73
Dividend yield: –